Literature DB >> 11254596

Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

P Richmond1, R Borrow, J Findlow, S Martin, C Thornton, K Cartwright, E Miller.   

Abstract

The polysaccharide capsule of serogroup C Neisseria meningitidis (MenC) has been integral to vaccine development. Licensed MenC vaccines contain the O-acetylated (OAc+) form of polysaccharide. Some MenC strains have de-O-acetylated (OAc-) polysaccharide, which may affect antibody specificity and functional activity when used in a vaccine. We evaluated an OAc-MenC conjugate-tetanus toxoid conjugate (MCC-TT) vaccine given concomitantly with whole-cell diphtheria-tetanus-pertussis, Haemophilus influenzae type b, and oral polio immunization in 83 infants at 2, 3, and 4 months of age. Serum bactericidal activities (SBA) against OAc+ and OAc- MenC strains and OAc+ and OAc- polysaccharide-specific immunoglobulin G (IgG) levels were evaluated. MCC-TT vaccine was well tolerated. All infants produced SBA titers of > or = 8 after a single dose at 2 months of age. The SBA geometric mean titer for OAc+ strain C11 increased from 2.7 (95% confidence interval [CI] 2.2 to 3.2) to 320 (95% CI, 237 to 432), 773 (95% CI, 609 to 982), and 1,063 (95% CI, 856 to 1319) after one, two, and three doses of MCC-TT, respectively. OAc- IgG levels were twice as high as OAc+ IgG levels after the primary series of MCC-TT vaccine, and the SBA was significantly higher against the OAc- MenC strain. Antibody responses to booster vaccination with either OAc+ MenC polysaccharide vaccine (MACP) or a fourth dose of MCC-TT at 14 months of age provided evidence of immunologic memory. The acetylation status of the booster vaccine influenced the specificity of the response, with significantly higher OAc- IgG levels and SBA after MCC-TT vaccine compared to MACP vaccine but similar OAc+ antibody levels. MCC-TT vaccine is highly immunogenic and primes for immunologic memory against OAc+ and OAc- MenC strains in infancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254596      PMCID: PMC98168          DOI: 10.1128/IAI.69.4.2378-2382.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Meningococcal disease falls in vaccine recipients.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  2000-04-14

2.  Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.

Authors:  R Booy; P T Heath; M P Slack; N Begg; E R Moxon
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

3.  Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report.

Authors:  K R Neal; J S Nguyen-van-Tam; R C Slack; E B Kaczmarski; A White; D A Ala'Aldeen
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

4.  Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom.

Authors:  R Borrow; E Longworth; S J Gray; E B Kaczmarski
Journal:  FEMS Immunol Med Microbiol       Date:  2000-07

5.  Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.

Authors:  R Borrow; P Richmond; E B Kaczmarski; A Iverson; S L Martin; J Findlow; M Acuna; E Longworth; R O'Connor; J Paul; E Miller
Journal:  FEMS Immunol Med Microbiol       Date:  2000-05

6.  The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines.

Authors:  J B Robbins; R Schneerson; P Anderson; D H Smith
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

7.  Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.

Authors:  L J Rubinstein; K E Stein
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

8.  The epidemiology of meningococcal disease in England and Wales, 1996 and 1997.

Authors:  M.E.B. Ramsay; M Collins; M Rush; E Kaczmarksi
Journal:  Euro Surveill       Date:  1997-10

9.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  23 in total

1.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  Safety of a new conjugate meningococcal C vaccine in infants.

Authors:  R Lakshman; I Jones; D Walker; K McMurtrie; L Shaw; G Race; S Choo; L Danzig; P Oster; A Finn
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

Review 3.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

4.  Synthesis and immunological study of α-2,9-oligosialic acid conjugates as anti-group C meningitis vaccines.

Authors:  Guochao Liao; Zhifang Zhou; Zhongwu Guo
Journal:  Chem Commun (Camb)       Date:  2015-06-14       Impact factor: 6.222

5.  Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.

Authors:  Peter C Fusco; Esmé K Farley; Chun-Hsien Huang; Samuel Moore; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

6.  First evidence for a covalent linkage between enterobacterial common antigen and lipopolysaccharide in Shigella sonnei phase II ECALPS.

Authors:  Tomasz K Gozdziewicz; Czeslaw Lugowski; Jolanta Lukasiewicz
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

7.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Adam Finn; Joanna Southern; Lindsey Ashton; Nick Andrews; Gouri Lal; Christine Riley; Rukhsana Rahim; Keith Cartwright; Geraldine Allan; Elizabeth Miller
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom.

Authors:  Jo Southern; Ray Borrow; Nick Andrews; Rhonwen Morris; Pauline Waight; Michael Hudson; Paul Balmer; Helen Findlow; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.